BioNTech SE Sponsored ADR (NASDAQ:BNTX) Receives Average Rating of “Moderate Buy” from Brokerages

BioNTech SE Sponsored ADR (NASDAQ:BNTX) has been assigned an average recommendation of “Moderate Buy” from the seventeen analysts that are currently covering the firm, MarketBeat reports. Four equities research analysts have rated the stock with a hold recommendation and thirteen have assigned a buy recommendation to the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $136.58.

BNTX has been the subject of a number of recent analyst reports. Leerink Partners set a $112.00 price target on shares of BioNTech in a research note on Monday, June 2nd. The Goldman Sachs Group initiated coverage on shares of BioNTech in a research note on Thursday, May 29th. They issued a “neutral” rating and a $110.00 target price for the company. Citigroup reaffirmed a “buy” rating and issued a $140.00 price objective (down from $145.00) on shares of BioNTech in a research report on Tuesday, May 6th. JPMorgan Chase & Co. cut their price objective on BioNTech from $120.00 to $116.00 and set a “neutral” rating for the company in a research report on Thursday, May 22nd. Finally, Wall Street Zen raised BioNTech from a “sell” rating to a “hold” rating in a research report on Saturday, June 7th.

BioNTech Trading Down 0.1%

BioNTech stock opened at $107.34 on Monday. The firm has a 50-day moving average of $108.11 and a 200-day moving average of $106.17. BioNTech has a one year low of $76.53 and a one year high of $131.49. The company has a debt-to-equity ratio of 0.01, a current ratio of 10.18 and a quick ratio of 10.02. The company has a market cap of $25.80 billion, a price-to-earnings ratio of -31.57 and a beta of 1.23.

Institutional Trading of BioNTech

Several large investors have recently made changes to their positions in the company. Raymond James Financial Inc. acquired a new stake in BioNTech in the fourth quarter valued at approximately $584,000. LPL Financial LLC grew its holdings in shares of BioNTech by 4.9% during the fourth quarter. LPL Financial LLC now owns 38,860 shares of the company’s stock valued at $4,428,000 after buying an additional 1,800 shares during the last quarter. Arrowstreet Capital Limited Partnership acquired a new position in shares of BioNTech during the fourth quarter valued at about $3,513,000. O Shaughnessy Asset Management LLC boosted its stake in BioNTech by 22.0% during the 4th quarter. O Shaughnessy Asset Management LLC now owns 7,600 shares of the company’s stock valued at $866,000 after purchasing an additional 1,373 shares during the last quarter. Finally, Franklin Resources Inc. boosted its stake in BioNTech by 3,942.1% during the 4th quarter. Franklin Resources Inc. now owns 136,786 shares of the company’s stock valued at $15,587,000 after purchasing an additional 133,402 shares during the last quarter. 15.52% of the stock is currently owned by institutional investors and hedge funds.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.